Chondrial Therapeutics

In November 2016, Deerfield led a Series A financing in Chondrial Therapeutics. Chondrial is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, such as Friedreich’s Ataxia (FA). Concurrent with our financing, Chondrial announced the licensing of a novel investigational technology, CTI-1601, for the treatment of FA from Indiana University Research and Technology Corp. (IURTC) and Wake Forest University Health Sciences. FA is a progressive disease that affects multiple body systems, particularly the brain and heart. FA is the most common ataxia in man and is caused by a deficiency of a key protein, frataxin, which is normally present in the mitochondria of all tissues.